预约演示
XNK Therapeutics’ Evencaleucel gains EMA recommendation
2024-01-16
临床2期基因疗法细胞疗法免疫疗法
Supporting XNK Therapeutics’ work is a team that includes experts in NK cell research. Credit: Gorodenkoff/Shutterstock.com.
XNK TherapeXNK Therapeuticsbased immunotherapy company, has received scientific recommendation from the European Medicines Agency’s (EMA) Committee for Advanced Therapies for its product Evencaleucel.
Evencaleucel is classified as a Somatic Cell Therapy Medicinal Product.
XNK Therapeuticson places Evencaleucel within the category of Advanced Therapy Medicinal Products. The pEuropean Medicines Agencyo maEMAacture the product is designed to produce autologouEvencaleucelller (NK) cell-based drug candidates.
Evencaleuceles are developed to act on malignant ailments, both as mono and combination therapies.
The platform features a clEvencaleucelturing system, which is pivotal for developing NK cell-based products.XNK
The manufacturing process involves the careful expansion and activation of NK cells derived from the peripheral blood of cancer patients.
XNK has a pipeline that includes treatments for both haematological malignancies and solid tumours.
Evencaleucel is the company’s most advanced product and is currently undergoing Phase II clinical trials, evaluating the cancery along with isatuximab, a CD38 antibody, to treat multiple myeloma.
XNKther asset, XNK02, is in advanced preclinical studhaematological malignancies MD Asolid tumoursr Center to potentially treat acute myeloid leukaemia.
Evencaleucel at treating bladder cancer, is in preclinical studies in partnership with the Karolinska University Hospital.isatuximabCD38multiple myeloma
Supporting XNK XNK02peutics’ innovative work is a team that includes experts in NMD Anderson Cancer CenterCanceracute myeloid leukaemia
XNK03ompany also benefitsbladder cancerved in-house good manufacturing practice facility.Karolinska University Hospital
XNK TherapeXNK Therapeuticscal officer Peter Hovstadius stated: “We are very pleased with EMA’s scientific recommendation. This is a necessary step in our regulatory approval journey and will make future interactions easier with the authorities.”
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
XNK Therapeuticst is independently produced and follows the highest standards of journalisEMA integrity. Topic sponsors are not involved in the creation of editorial content.
Free WhitepaperCell and gene therapies: Pipe dream to pipeline
The cell and gene industry is gaining momentum, with a new wave of therapies promising to transform the way doctors treat, and even cure, disease. In this report, Cytiva and GlobalData have collaborated to explore the rise of the cell and gene therapy industries, the current state of the market, present and future opportunities for advancement, and the challenges that lie ahead.
By Cytiva Thematic
-->Cytiva
By Cytiva Thematics case study, you acknowledge that GlobalData may share your information with Cytiva Thematic and that your personal data will be used as described in their Privacy Policy
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
药物
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。